Financial Profile
  
   
UNAUDITED FINANCIAL RESULTS
FOR THE QUARTER ENDED 31ST MARCH, 2003
  
Rs in millions
Quarter Ended
Year Ended
31.03.2003
31.03.2002
31.03.2003
31.03.2002
(Audited)
1. Net Sales & Income from Operations
3881.5
3943.1
15724.4
14005.1
2. Other Income
110.7
20.5
258.1
283.6
3. Total Expenditure
a) (Increase)/decrease in Stock-in-trade
(248.7)
(444.0)
(787.3)
(850.9)
b) Consumption of Materials
2234.5
2002.4
7968.2
6907.5
c) Staff Cost
191.3
178.4
728.8
632.5
d) Other Expenditure
1233.9
1318.2
4651.0
4272.1
4. Interest
8.8
5.0
16.3
21.0
5. Depreciation
66.7
71.5
283.2
212.8
6. Profit (+)/Loss (-) before Tax (1+2-3-4-5)
505.7
832.1
3122.3
3093.7
7. Provision for Taxation
38.4
215.0
647.5
742.5
8. Net Profit (+)/Loss (-) after Tax (6-7)
467.3
617.1
2474.8
2351.2
9. Paid-up Equity Share Capital
599.7
599.7
599.7
599.7
10. Reserves excluding Revaluation Reserves (as per balance sheet of previous accounting year)
-  
- 
- 
8197.0
11. Earning per Share
*Not Annualised
*7.79
*10.29
41.27
34.62
12. Aggregate of Non-Promoter Shareholding
- Number of Shares
- Percentage of Shareholding
36022237
60.06
36044037
60.10
36022237
60.06

36044037
60.10

Notes :

  1. The provision for tax includes deferred taxation.
  2. The Company is exclusively in the pharmaceutical business segment.
  3. The figures of the previous year have been regrouped to render them comparable with the figures of the current year.
  4. The above results were taken on record at the meeting of the Board of Directors held on 25th April, 2003.
 

 

Mumbai
25th April, 2003

By order of the Board
For CIPLA LIMITED



M. K. Hamied
Joint Managing Director